Episode
HR-Positive Metastatic Breast Cancer — An Interview with Dr Seth Wander on Optimizing Biomarker Assessment and Related Treatment Decision-Making
- Published
- Apr 16, 2026
- Duration seconds
- 3613
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/oncology-today-with-dr-neil-love-1004241/episodes/hr-positive-metastatic-breast-cancer-an-interview-with-dr-seth-wander-on-optimizing-biomarker-assessment-and-related-treatment-decision-making/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241/hr-positive-metastatic-breast-cancer-an-interview-with-dr-seth-wander-on-optimizing-biomarker-assessment-and-related-treatment-decision-making.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Dr Seth Wander from Massachusetts General Hospital in Boston discusses the role of biomarker assessment in the management of HR-positive metastatic breast cancer. CME information and select publications here .